THE REOPEN-AMI STUDY - Intracoronary Nitroprusside Versus Adenosine in Acute Myocardial Infarction
Status:
Completed
Trial end date:
2011-09-01
Target enrollment:
Participant gender:
Summary
The occurrence of no-reflow phenomenon after recanalization of the infarct related artery in
acute myocardial infarction is described in up to 40% of cases. This event is associated with
a worse prognosis at follow up and an unfavourable left ventricular remodelling . Two main
pathogenetic mechanisms cause no-reflow: distal embolization and ischemia-reperfusion injury.
Due to the multifactorial pathogenesis of no-reflow during acute MI a combined mechanic and
pharmacologic approach is believed to offer a better solution for achieving optimal
microvascular reperfusion. Thus, in this randomized study we will assess the effect of
nitroprusside or adenosine in adjunct to current best therapy (thrombus aspiration and
IIb-IIIa antagonists) for ST elevation MI using ST segment resolution on standard 12 leads
ECG as primary endpoint of myocardial reperfusion.